TAMI SHELDON: Open Payments
NPI 1164857504 · DAVENPORT, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,484 in 60 payments from 31 companies in 2025. Trend: 2023 $1,469 · 2024 $1,582 · 2025 $1,484
Food & beverage: $1,070Long term medical supply or device loan: $399Education: $16
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $538 |
| Janssen Biotech, Inc. | 13 | $191 |
| ABBVIE INC. | 1 | $75 |
| Daiichi Sankyo Inc. | 3 | $61 |
| PFIZER INC. | 3 | $58 |
| GlaxoSmithKline, LLC. | 2 | $51 |
| Exelixis Inc. | 2 | $42 |
| TerSera Therapeutics LLC | 1 | $40 |
| PharmaEssentia USA Corporation | 2 | $36 |
| Lilly USA, LLC | 1 | $26 |
Products named: KISQALI, ERLEADA, Epkinly, Enhertu, OJJAARA, RYBREVANT, SCEMBLIX, CABOMETYX.
Industry payments across IA — which companies pay providers there.
